What is retatrutide?

Retatrutide is an investigational weight-loss and metabolic medication being developed by Eli Lilly. It is a once-weekly injectable that acts on three hormone receptors — GIP, GLP-1, and glucagon — which is why it's sometimes called a 'triple agonist.' Important: retatrutide is still in clinical trials. It is not FDA-approved, and it is not legally available by prescription or from licensed U.S. pharmacies. Any product sold online as retatrutide today is unregulated and not verified for safety.

Why there's so much interest

Early clinical-trial data reported in medical journals generated significant attention because of the amount of weight participants lost. Those results come from tightly controlled studies and have not translated into an approved, prescribable medication.

Because it targets three pathways instead of the one (semaglutide) or two (tirzepatide) used by current medications, retatrutide is frequently discussed as a potential 'next generation' option — but 'potential' is the key word until trials are complete and regulators review the data.

What this means for you today

If you want to start physician-supervised weight-loss treatment now, the appropriate options are FDA-approved GLP-1 medications and physician-supervised compounded therapies your clinician determines are right for you — not a research chemical purchased online. Our physicians can help you build a plan with medications that are actually available and monitored.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.